Hester J. Scheffer

ORCID: 0000-0001-6298-383X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Microbial Inactivation Methods
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Treatments and Studies
  • Microfluidic and Bio-sensing Technologies
  • Renal cell carcinoma treatment
  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Magnetic and Electromagnetic Effects
  • Plasma Applications and Diagnostics
  • MRI in cancer diagnosis
  • Toxin Mechanisms and Immunotoxins
  • Plant tissue culture and regeneration
  • Radiomics and Machine Learning in Medical Imaging
  • Medical Imaging Techniques and Applications
  • Ultrasound and Cavitation Phenomena
  • Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cancer Genomics and Diagnostics
  • Liver Disease Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Ultrasound and Hyperthermia Applications
  • Vascular Malformations and Hemangiomas
  • Neuroendocrine Tumor Research Advances

Noordwest Ziekenhuisgroep
2023-2025

Amsterdam University Medical Centers
2018-2024

Northwest Hospital
2024

Cancer Center Amsterdam
2019-2024

Vrije Universiteit Amsterdam
2018-2024

Amsterdam UMC Location Vrije Universiteit Amsterdam
2012-2023

Amsterdam UMC Location University of Amsterdam
2015-2021

University Medical Center Utrecht
2021

München Klinik Bogenhausen
2021

University of Amsterdam
2019-2020

Radiofrequency ablation (RFA) and microwave (MWA) are widely accepted techniques to eliminate small unresectable colorectal liver metastases (CRLM). Although previous studies labelled thermal inferior surgical resection, the apparent selection bias when comparing patients with disease candidates, superior safety profile, competitive overall survival results for more recent reports mandate setup of a randomized controlled trial. The objective COLLISION trial is prove non-inferiority compared...

10.1186/s12885-018-4716-8 article EN cc-by BMC Cancer 2018-08-15

There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear definitions of oncologic end points. This document proposes standardized for a broad range with recommendations on how to uniformly document, analyze, and report outcomes. The initiative was coordinated by the Society Interventional Oncology in collaboration Definition Assessment Time-to-Event End Points Cancer Trials, DATECAN, group. According predefined criteria,...

10.1148/radiol.2021203715 article EN Radiology 2021-09-28
Susan van der Lei Robbert S. Puijk Madelon Dijkstra Hannah H. Schulz Danielle J. W. Vos and 90 more Jan J. J. de Vries Hester J. Scheffer Birgit I. Lissenberg‐Witte Luca Aldrighetti Mark J. Arntz Maarten W. Barentsz Marc G. Besselink B. Bracke Rutger C. G. Bruijnen Tineke E. Buffart Mark C. Burgmans T. Chapelle Mariëlle M.E. Coolsen Sanne de Boer Francesco De Cobelli Koert de Jong Johannes H.W. de Wilt Arjen L. Diederik Anniek M.C. Dooper Werner A. Draaisma Hasan H. Eker Joris I. Erdmann Jurgen J. Fütterer Bart Geboers Gerie Groot Jeroen Hagendoorn Henk H. Hartgrink Karin Horsthuis Rob Hurks Sjoerd F.M. Jenniskens Matthijs Kater Geert Kazemier Jakob W. Kist Joost M. Klaase Robrecht R M M Knapen Johan W. H. Kruimer Armand B G N Lamers Wouter K. G. Leclercq Gerrit‐Jan Liefers Eric R. Manusama Mark A. Meier Marleen C. A. M. Melenhorst J. Sven D. Mieog Q. Molenaar Karin Nielsen Maarten W. Nijkamp Vincent B. Nieuwenhuijs Irene M G C Nota Bart Op de Beeck Christiaan G. Overduin Gijs A. Patijn Fons H. Potters Francesca Ratti Floris J. Rietema Simeon J. S. Ruiter Evelien A. C. Schouten Wilhelmina H. Schreurs G Serafino Colin Sietses Gerrit D. Slooter Maarten L. J. Smits Ezgi A Soykan Gert-Jan Spaargaren Martijn W.J. Stommel Florentine E. F. Timmer Laurens J. van Baardewijk Ronald M. van Dam Otto M. van Delden Bente A. T. van den Bemd Janneke E. van den Bergh Peter B. van den Boezem Christiaan van der Leij R.W. van der Meer Bram B.M. van der Meijs Augustinus P. T. van der Ploeg J.J. van der Reijden Peter van Duijvendijk Arian R. van Erkel Anne M. van Geel N. Tjarda van Heek Christiaan J. van Manen Carla S. P. van Rijswijk Jan Hein T M van Waesberghe Kathelijn S. Versteeg Ted Vink I. Zijlstra Barbara M. Zonderhuis Rutger‐Jan Swijnenburg M. Petrousjka van den Tol Martijn R. Meijerink

10.1016/s1470-2045(24)00660-0 article EN The Lancet Oncology 2025-01-01

Purpose To (a) investigate the safety of percutaneous irreversible electroporation (IRE) for locally advanced pancreatic cancer and (b) evaluate quality life (QOL), pain perception, efficacy in terms time to local progression, event-free survival, overall survival (OS). Materials Methods The study was approved by review board (NL42888.029.13). All patients provided written informed consent participation, ablation procedure, data usage. Between January 2014 June 2015, 25 with histologically...

10.1148/radiol.2016152835 article EN Radiology 2016-09-07

Background Patients with locally advanced pancreatic cancer have a dismal prognosis, median overall survival (OS) of 12–14 months systemic therapies. Irreversible electroporation (IRE), nonthermal ablative technique, may prolong patients cancer. Purpose To investigate the safety and efficacy percutaneous IRE for recurring in prospective phase II trial. Materials Methods Between December 2012 September 2017, participants or postresection local recurrence were prospectively treated CT-guided...

10.1148/radiol.2019191109 article EN Radiology 2019-11-05

Purpose: Local tumor ablation through irreversible electroporation (IRE) may offer a novel therapeutic option for locally advanced pancreatic cancer (LAPC). It also serve as means of in vivo vaccination. To obtain evidence the induction systemic antitumor immunity following local IRE-mediated ablation, we performed an explorative immune monitoring study. Methods: In ten patients enrolled clinical trial exploring safety, feasibility, and efficacy percutaneous image-guided IRE LAPC, determined...

10.1080/2162402x.2019.1652532 article EN OncoImmunology 2019-08-28

The guidelines for metastatic colorectal cancer crudely state that the best local treatment should be selected from a ‘toolbox’ of techniques according to patient- and treatment-related factors. We created an interdisciplinary, consensus-based algorithm with specific resectability ablatability criteria liver metastases (CRLM). To pursue consensus, members multidisciplinary COLLISION COLDFIRE trial expert panel employed RAND appropriateness method (RAM). Statements regarding patient, disease,...

10.3390/cancers12071779 article EN Cancers 2020-07-03

To retrospectively analyse the safety and efficacy of radiofrequency ablation (RFA) versus microwave (MWA) in treatment unresectable colorectal liver metastases (CRLM) proximity to large vessels and/or major bile ducts. A database search was performed include patients with histologically proven 18F–FDG–PET avid CRLM who were treated RFA or MWA between January 2001 September 2014 a single centre. All lesions that considered have peribiliary perivascular location included. Univariate logistic...

10.1007/s00270-016-1413-3 article EN cc-by CardioVascular and Interventional Radiology 2016-07-07

Background Irreversible electroporation (IRE), an ablative technique that uses high-voltage electrical pulses, has shown promise for eradicating tumors near critical structures, including blood vessels and bile ducts. Purpose To investigate the efficacy safety of IRE colorectal liver metastases (CRLMs) unsuitable resection or thermal ablation because proximity to structures further systemically administered treatments. Materials Methods Between June 2014 November 2018, participants with...

10.1148/radiol.2021203089 article EN Radiology 2021-03-16

To analyze long-term oncological outcomes of open and percutaneous thermal ablation in the treatment patients with colorectal liver metastases (CRLM).This assessment from a prospective, longitudinal tumor registry included 329 who underwent 541 procedures for 1350 CRLM January 2010 to February 2021. Three cohorts were formed: 2010-2013 (129 [53 percutaneous]), 2014-2017 (206 [121 percutaneous]) 2018-2021 [135 percutaneous]). Local progression-free survival (LTPFS) overall (OS) data estimated...

10.1007/s00270-022-03152-9 article EN cc-by CardioVascular and Interventional Radiology 2022-05-18

Irreversible electroporation (IRE) uses short duration, high-voltage electrical pulses to induce cell death via nanoscale defects resulting from altered transmembrane potential. The technique is gaining interest for ablations in unresectable pancreatic and hepatobiliary cancer. Metal stents are often used palliative biliary drainage these patients, but currently seen as an absolute contraindication IRE due the perceived risk of direct heating metal its surroundings. This study investigates...

10.1371/journal.pone.0148457 article EN cc-by PLoS ONE 2016-02-04

Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique that has shown promise for the of lesions in proximity to vital structures such as blood vessels and bile ducts. The primary aim COLDFIRE-2 trial investigate efficacy IRE unresectable, centrally located colorectal liver metastases (CRLM). Secondary outcomes are safety, technical success, accuracy contrast-enhanced (ce)CT (18)F-FDG PET-CT detection local progression (LTP).In this single-arm, multicenter phase...

10.1186/s12885-015-1736-5 article EN cc-by BMC Cancer 2015-10-24
Coming Soon ...